Nataliya Mar

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

Thomas Powles, Begoña P. Valderrama, Shilpa Gupta et al. · New England Journal of Medicine · 2024 · 764 citations

Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Peter H. O’Donnell, Matthew I. Milowsky, Daniel P. Petrylak et al. · Journal of Clinical Oncology · 2023 · 157 citations · Full text

LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)

Thomas Powles, Begoña P. Valderrama, Shilpa Gupta et al. · Annals of Oncology · 2023 · 131 citations · Full text

Urology, Genitourinary Cancer, Medicine +6

Potential Costs of Inappropriate Use of Proton Pump Inhibitors

Antonio Mendoza Ladd, Georgia Panagopoulos, Joshua Cohen et al. · The American Journal of the Medical Sciences · 2013 · 67 citations

Potential Costs, Medicine, Pharmacoeconomics +5

Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response

Vladimir Gotlib, Samer K. Khaled, Igor Lapko et al. · Anti-Cancer Drugs · 2006 · 46 citations

Skin Cancer, Gastrointestinal Oncology, Medicine +13